VLB-01 / MarcoPolo Pharma - LARVOL DELTA

Development of the reverse genetics system for viral hemorrhagic septicemia virus genotype IVa and its application in antiviral compound screening. (PubMed, Virol Sin) - "Time-of-addition assays further revealed that xanthohumol and rottlerin targeted the viral replication stage, while octyl gallate interfered with viral internalization. This reverse genetics system provides a versatile platform for studying VHSV pathogenesis, developing live-attenuated vaccines, and screening antiviral compounds, enhancing our understanding of this pathogen and offering new tools for aquaculture disease management."

Journal • Hematological Disorders

MarcoPolo Pharmaceuticals announces a positive phase II-III study in patients with complex partial seizure for compound VLB-01 (First Word Pharma) - P2/3, N=NA; "The efficacy was clinically and statistically significant with median percent seizure reduction of about 60% for VLB-01, three times above the placebo (p<0.0001). Similarly the response rate was about two times for VLB-01 compared to placebo. The rate of seizure-free patients ranged from 19 to 33% for VLB-01 compared to 10 to 17% for placebo....We [MarcoPolo] are committed to have this product approved in the Russian Federation for the end of this year or early next year."

Anticipated non-US regulatory • P2/3 data • Epilepsy

Isolation and identification of a viral haemorrhagic septicaemia virus (VHSV) isolate from wild largemouth bass Micropterus salmoides in China. (PubMed, J Fish Dis) - "VHSVLB2018 was re-isolated from dead fish and confirmed by RT-PCR. Together, this is the first report of isolation and identification of a VHSV isolate from wild largemouth bass in China."

Journal